ArticleFrontiers in cardiovascular medicine2026
Prognostic value of soluble ST2 in cardiac magnetic resonance defined myocardial infarction with non-obstructive coronary arteries.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac magnetic resonance (CMR) plays an essential role in identifying the underlying etiology of myocardial infarction with non-obstructive coronary arteries (MINOCA). However, risk stratification in patients with CMR-confirmed MINOCA remains insufficiently defined. Soluble suppression of tumorigenicity 2 (sST2), a biomarker related to myocardial fibrosis and adverse cardiac remodeling, may provide additional prognostic information in this population. This study aimed to evaluate the prognostic value of sST2 in patients with CMR-confirmed MINOCA. Methods: This single-center retrospective study included patients suspected of MI who underwent coronary angiography and completed CMR during hospitalization. MACE included all-cause death, recurrent MI, stroke, heart failure, arrhythmia, and angina pectoris. MINOCA was defined by evidence of ischemia or infarction on CMR. sST2 was tested using an immunoassay kit according to the protocol during hospitalization. Results: A total of 97 patients with CMR-confirmed MINOCA were included. During a median follow-up of 24.2 months, 33 patients experienced MACE. Patients with MACE had significantly higher sST2 levels and worse CMR parameters, including lower left ventricular ejection fraction, greater late gadolinium enhancement extent, larger left ventricular end-systolic volume index, and impaired global longitudinal strain (GLS). Multivariable Cox regression analysis showed that sST2 (HR 1.010, 95% CI 1.003-1.017, Conclusions: Elevated sST2 is independently associated with adverse outcomes in patients with CMR-confirmed MINOCA. sST2 may serve as a practical biomarker for risk stratification in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.